Preferential interneuron survival in the transition zone of 3-NP-induced striatal injury in rats

Journal of Neuroscience Research

Volumn 89, Issue 5, 2011, Pages 744-754

  Mu, Shuhua ^a   Ouyang, Lisi ^a   Liu, Bingbing ^a   Zhu, Yaxi ^a   Li, Keyi ^a   Zhan, Mali ^a   Liu, Zongwei ^a   Jia, Yu ^a   Lei, Wanlong ^a   Reiner, A ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

3 NP; Interneuron; Striatum; Transition zone

Indexed keywords

3 NITROPROPIONIC ACID; CALRETININ; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPEPTIDE Y; PARVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CELL STRUCTURE; CELL SURVIVAL; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; INTERNEURON; MALE; NERVE CELL NECROSIS; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CELL SURVIVAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; INTERNEURONS; MALE; NERVE DEGENERATION; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME;

EID: 79952525144     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22591     Document Type: Article

References (43)

1. Albin RL, Tagle DA. 1995. Genetics and molecular biology of Huntington's disease. Trends Neurosci 18: 11-14.
2. Albin RL, Young AB, Penney JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375.
3. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BF, Hyman BT. 1993. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192
4. Cicchetti F, Gould PV, Parent A. 1996. Sparing of striatal neurons coexpressing calretinin and substance P (NK-1) receptor in Huntington's disease. Brain Res 730: 232-237.
5. Cicchetti F, Prensa L, Wu Y, Parent A. 2000. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Rev 34: 80-101
6. Cipriani S, Bizzoco E, Gianfriddo M, Melani A, Vannucchi MG, Pedata F. 2008. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp Neurol 213: 163-170.
7. Coyle JT, Schwarcz R. 1976. Lesion of striatal neurons with kainic acid provides a model for Huntington's disease. Nature 263: 244-246.
8. Dawbarn D, DeQuidt ME, Emson PC. 1985. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 340: 251-261.
9. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. 2004. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 27: 143-164.
10. Du C, Hu R, Csernansky CA, Liu XZ, Hsu CY, Choi DW. 1996. Additive neuroprotective effects of dextrorphan and cycloheximide in rats subjected to transient focal cerebral ischemia. Brain Res 718: 233-236.
11. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardso EPJr. 1987. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 46: 12-27.
12. Ferrante RJ, Kowall NW, Richardson EPJr. 1991. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 11: 3877-3887.
13. Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF. 1993. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp Neurol 119: 46-71.
14. Figueredo-Cardenas G, Chen Q, Reiner A. 1997. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 146: 444-457.
15. Folstein SE, Leigh J, Parhad IM, Folstein MF. 1986. The diagnosis of Huntington's disease. Neurology 36: 1279-1283.
16. Furtado JCS, Mazurek MF. 1996. Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease. Exp Neurol 138: 158-168.
17. Galeffi F, Sinnar S, Schwartz-Bloom RD. 2000. Diazepam promotes ATP recovery and prevents cytochromec release in hippocampal slices after in vitro ischemia. J Neurochem 75: 1242-1249.
18. Giampa C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco1 FR. 2009. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur J Neurosci 29: 902-910.
19. Graveland GA, Williams RS, DiFiglia M. 1985. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227: 770.
20. Hantraye P, Riche D, Maziere M, Isacson O. 1990. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate putamen in the baboon. Exp Neurol 108: 91-104.
21. Hedreen JC, Folstein SE. 1995. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 54: 105-120.
22. Heizmann CW, Braun K. 1995. Calcium regulation by calciurnbinding proteins in neurodegenerarive disorders. Berlin: Springer-Verlag.
23. Her LS, Goldstein LS. 2008. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 28: 13662-13672.
24. Huang Q, Zhou D, Sapp E, Aizawa H, Bird ED, Vonsattelt JP, Difiglia M. 1995. Quinolinic acid-induced increases in calbindin D28k immunoreacticity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience 65: 397-407.
25. Kolb B, Holmes C. 1983. Neonatal motor cortex lesions in the rat: Absence of sparing of motor behaviours and impaired spatial learning concurrent with abnormal cerebral morphogenesis. Behav Neurosci 97: 697-709.
26. Kowall NW, Ferrante RJ, Martin JB. 1987. Patterns of cell loss in Huntington's disease. Trends Neurosci 10: 24-29.
27. Liu S, Levine SR, Richard Winn H. 2010. Targeting ischemic penumbra: part I-from pathophysiology to therapeutic strategy. J Exp Stroke Transl Med 3: 47-55.
28. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M. 1991. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18: 492-498.
29. Massouh M, Wallman MJ, Pourcher E, Parent A. 2008. The fate of the large striatal interneurons expressing calretinin in Huntington's disease. Neurosci Res 62: 216-224
30. McGeer EG, McGeer PL. 1976. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263: 517-519.
31. Miller PJ, Zaborszky L. 1997. 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease. Exp Neurol 146: 212-229.
32. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. San Diego: Academic Press.
33. Perlson E, Maday S, Fu MM, Moughamian AJ, Holzbaur ELF. 2010. Retrograde axonal transport: pathways to cell death? Trends Neurosci 33: 335-344.
34. Reiner A, Albin RL, Anderson KD, D'Amatos CJ, Penneyt JB, Young AB. 1988. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85: 5733-5737.
35. Schwarcz R, Whetsell WO, Mangano RM. 1983. Quinolinic acid: An endogenous metabolite that produces axonsparing lesions in rat brain. Science 219: 316-318.
36. Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL. 1998. Comparison of intrastriatxi, injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Reg Neum-Psychopharmad Bid Psychiatry 22: 1217-1240
37. Sugars KL, Rubinsztein DC. 2003. Transcriptional abnormalities in Huntington disease. Trends Genet 19: 233-238.
38. Sun Z, Xie J, Reiner A. 2002. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease. Exp Neurol 176: 55-65.
39. Vonsattel JP, Meyers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EPJr. 1985. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577.
40. Voogd J, Feirabend HKP. 1981. Methods in neurobiology, vol 2. New York: Elsevier. p 301-364.
41. Vorhees CV, Williams MT. 2006. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1: 848-858.
42. Wang J, Chambers G, Cottrell JE, Kass IS. 2000. Differential fall in ATP accounts for effects of temperature on hypoxic damage in rat hippocampal slices. J Neurophysiol 83: 3462-3472.
43. Wullner U, Young AB, Penney JB, Beal MF. 1994. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 63: 1772-1781.